On August 10, Moderna, Inc. rose 5.15% in pre-market trading, trading at $62.12/share, with turnover of $3.10 million. The stock continues to gain momentum following the FDA approval of the company's seasonal influenza vaccine mFLUSIVA.

The approval, announced earlier this month, marks a milestone as the first mRNA vaccine to enter the flu market and Moderna's fourth FDA-cleared product in the US. mFLUSIVA is approved for adults aged 50 and above, with the company expecting availability through select retail channels in the coming weeks to cover the 2026-2027 respiratory virus season. The vaccine is also currently under regulatory review in Australia, Canada, and Europe.

The approval came after an earlier regulatory setback, making it a significant commercial victory for Moderna. Previously, Bank of America adjusted its price target on Moderna to $38 from $34 while maintaining an Underperform rating, and the analyst consensus target stands at $50.53. Market confidence in Moderna's mRNA platform expansion and commercialization prospects continues to strengthen.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)